Assessing neuropsychological changes in pharmacological trials.

abstract：:A correlation was found among the degree of memory loss, intellectual impairment, the quantity of senile plaques, and a decrease in choline acetyltransferase and acetylcholinesterase activity in patients affected by senile dementia of the Alzheimer type. In this study, patients were subjected to a series of computeriz...

journal_title：Clinical neuropharmacology

authors： Agnoli A,Martucci N,Manna V,Conti L,Fioravanti M

更新日期：1983-01-01 00:00:00

abstract：:We report on a schizophrenic patient whose tardive dystonia, delusions, and auditory hallucinations showed remarkable concurrent improvement after replacing haloperidol with risperidone. The present finding suggests that the 5-hydroxytryptamine-2 (5-HT2) antagonistic action of risperidone has brought about the improve...

journal_title：Clinical neuropharmacology

authors： Yoshida K,Higuchi H,Hishikawa Y

更新日期：1998-01-01 00:00:00

abstract：:We studied the effect of chronic bromocriptine cotherapy on levodopa kinetics in seven patients with Parkinson's disease who were receiving levodopa therapy. Plasma levodopa concentrations were measured after a standard oral levodopa fasting dose over a 5-hour period, on two different sessions, without and with bromoc...

journal_title：Clinical neuropharmacology

authors： Contin M,Riva R,Martinelli P,Albani F,Baruzzi A

更新日期：1992-12-01 00:00:00

abstract：OBJECTIVES:Ponezumab is a humanized antiamyloid beta (Aβ) monoclonal antibody designed to treat Alzheimer disease (AD). METHODS:This randomized, double-blind, single-dose-escalation study evaluated the safety, pharmacokinetics, and pharmacodynamics of 0.1, 0.3, 1, 3, and 10 mg/kg ponezumab (n = 4, 4, 4, 6, and 8, resp...

journal_title：Clinical neuropharmacology

authors： Landen JW,Zhao Q,Cohen S,Borrie M,Woodward M,Billing CB Jr,Bales K,Alvey C,McCush F,Yang J,Kupiec JW,Bednar MM

更新日期：2013-01-01 00:00:00

abstract：:Antiepileptic drugs (AEDs) suppress seizures by selectively modifying the excitability of neurons and blocking seizure firing with minimal disturbance of nonepileptic activity. All AEDs have been shown to work by at least one of 3 main mechanisms of action: through modulation of voltage-gated ion channels, enhancement...

journal_title：Clinical neuropharmacology

authors： Biton V

更新日期：2007-07-01 00:00:00

abstract：:Chronic treatment of rats with dexfenfluramine decreased the concentrations of circulating corticosterone, fatty acid, glycerol, and triacylglycerol after feeding a test load of fructose. It also decreased the rise in adrenalin in the blood of rats that were anaesthetized with urethane. These effects of dexfenfluramin...

journal_title：Clinical neuropharmacology

authors： Brindley DN

更新日期：1988-01-01 00:00:00

abstract：:Monoamine oxidase (MAO) inhibitors (MAOIs) provide effective alternative therapy for those patients with major depression who do not respond to tricyclic antidepressants or such related compounds as the selective serotonin reuptake inhibitors. This article reviews studies on the efficacy of both the classical MAOIs an...

journal_title：Clinical neuropharmacology

authors： Nolen WA,Hoencamp E,Bouvy PF,Haffmans PM

更新日期：1993-01-01 00:00:00

abstract：OBJECTIVE:To review the current evidence on the effectiveness of second-generation antipsychotics (SGAs) in the treatment of tardive dystonia (TDt) and give recommendations for treatment. METHODS:Medline/PubMed/Psyclit/Embase database searches were conducted in January 2015, and a manual review of references within th...

journal_title：Clinical neuropharmacology

authors： Pinninti NR,Faden J,Adityanjee A

更新日期：2015-09-01 00:00:00

abstract：BACKGROUND:Catatonia is a severe condition in patients. Electroconvulsive treatment or medication with benzodiazepines and/or antipsychotics are regarded as standard treatment. CASE PRESENTATION:We report a case of a patient with catatonic features in whom electroconvulsive treatment and benzodiazepine and/or antipsyc...

journal_title：Clinical neuropharmacology

authors： Sato Y,Shinozaki M,Okayasu H,Yasui-Furukori N,Shimoda K

更新日期：2020-05-01 00:00:00

abstract：:In nine patients with orthostatic hypotension due to multiple system atrophy, the effects of octreotide (100 micrograms s.c.), a somatostatin analogue, on blood pressure (BP), heart rate (HR), and norepinephrine (NE) plasma levels after 60 degrees head up tilt test were evaluated by a randomly controlled study. Octreo...

journal_title：Clinical neuropharmacology

authors： Bordet R,Benhadjali J,Destée A,Belabbas A,Libersa C

更新日期：1995-02-01 00:00:00

abstract：:The results of pharmacokinetic studies of two recent 5-HT uptake inhibitors, zimelidine and fluoxetine, have pointed to the inadequacy of open-dose rising studies for establishing the most appropriate dose of new antidepressants. High plasma concentrations of the active metabolites, norzimelidine and norfluoxetine, we...

journal_title：Clinical neuropharmacology

authors： Montgomery SA,Baldwin D,Shah A,Green M,Fineberg N,Montgomery D

更新日期：1990-01-01 00:00:00

abstract：:Depression frequently coexists with dementia, although in many cases the depression is not recognized clinically. Depression represents a major additional burden in dementia, not only for the patients but also for families, caregivers, and, economically, society as a whole. However, depression in patients with dementi...

journal_title：Clinical neuropharmacology

authors： De Vry J,Fritze J,Post RM

更新日期：1997-02-01 00:00:00

abstract：OBJECTIVES:To describe further the phenomenology of drug-induced psychosis (DIP) in patients with Parkinson disease (PD) and assess which items on two common psychosis rating instruments-the Brief Psychiatric Rating Scale (BPRS) and the Neuropsychiatric Inventory (NPI)-are the best measure of DIP by comparing them with...

journal_title：Clinical neuropharmacology

authors： Chou KL,Messing S,Oakes D,Feldman PD,Breier A,Friedman JH

更新日期：2005-09-01 00:00:00

abstract：OBJECTIVE:The aim of this study was to report the case of a male patient with Parkinson disease who developed brachial plexopathy (BP) due to varicella-zoster virus, which was successfully treated with human immunoglobulin. METHOD:We report the case of a 75-year-old male subject with a diagnosis of Parkinson disease w...

journal_title：Clinical neuropharmacology

authors： Sáenz-Farret M,Sandoval-Rodríguez V,Paz-Navarro CE,Zúñiga-Ramírez C

更新日期：2017-01-01 00:00:00

abstract：:Glutamate is the predominant excitatory neurotransmitter of the basal ganglia, where it acts on ionotropic and metabotropic receptors. In the best studied of the basal ganglia disorders, Parkinson's disease, there is compelling evidence that the activities of glutamatergic pathways are altered. Of particular importanc...

journal_title：Clinical neuropharmacology

authors： Greenamyre JT

更新日期：2001-03-01 00:00:00

abstract：:Several recent reports attest to zolpidem's strong potential for abuse, dependence, and severe withdrawal symptoms upon its discontinuation. We report, for the first time, on 1 case of heavy zolpidem abuse and dependence with severe withdrawal symptoms twice treated safely and successfully with pregabalin, a newer ant...

journal_title：Clinical neuropharmacology

authors： Oulis P,Nakkas G,Masdrakis VG

更新日期：2011-03-01 00:00:00

abstract：:Myoclonic status epilepticus (MSE) in patients without epilepsy, or de novo MSE, is a rare condition associated with several acute symptomatic etiologies, including drugs and toxins. We describe a 94-year-old woman with Alzheimer dementia and long use of mirtazapine 30 mg/d and alprazolam 1 mg/d who developed MSE appr...

journal_title：Clinical neuropharmacology

authors： Vicente Ferreira Naves P,Calderaro M,Caboclo LO

更新日期：2018-07-01 00:00:00

abstract：OBJECTIVES:Treatment-resistant depression is a common occurrence in clinical practice as well as combination treatment with 2 different antidepressants. In the present case series, we study the effectiveness of the addition of reboxetine, during 12 weeks, to 14 outpatients diagnosed with major depressive disorder, acco...

journal_title：Clinical neuropharmacology

authors： López-Muñoz F,Rubio G,Alamo C,García-García P,Pardo A

更新日期：2006-07-01 00:00:00

abstract：:Midazolam, a potent short-acting benzodiazepine, is a safe and highly effective agent for the control of status epilepticus. Its efficacy in the control of neonatal seizures, however, has not been determined. Six neonates (aged 1-9 days; gestation, 30-41 weeks) developed seizures from a variety of causes. In each case...

journal_title：Clinical neuropharmacology

authors： Sheth RD,Buckley DJ,Gutierrez AR,Gingold M,Bodensteiner JB,Penney S

更新日期：1996-04-01 00:00:00

abstract：:Studies assessing the effect of transdermal nicotine in Parkinson's disease (PD) have generated mixed results regarding its efficacy to treat motor and cognitive deficits. These studies generally reported good tolerability in nonsmoking PD patients. The authors report the tolerability data of an open trial with transd...

journal_title：Clinical neuropharmacology

authors： Lemay S,Blanchet P,Chouinard S,Masson H,Soland V,Bédard MA

更新日期：2003-09-01 00:00:00

abstract：:Patients with Parkinson's disease (PD) can experience cognitive impairment. There are currently no medications indicated for the treatment of cognitive impairment in PD. Clinicians are faced with the dilemma as to whether or not to treat patients with PD with the acetylcholinesterase inhibitors that are currently appr...

journal_title：Clinical neuropharmacology

authors： Richard IH,Justus AW,Greig NH,Marshall F,Kurlan R

更新日期：2002-11-01 00:00:00

abstract：:Heart rate variability (HRV) reflects the cardiac autonomic regulation, and reduced HRV is considered a pathophysiological link between depression and cardiovascular mortality. So far, there is only limited information on the effects of venlafaxine and mirtazapine on HRV.We studied 28 nondepressed controls and 41 mode...

journal_title：Clinical neuropharmacology

authors： Terhardt J,Lederbogen F,Feuerhack A,Hamann-Weber B,Gilles M,Schilling C,Lecei O,Deuschle M

更新日期：2013-11-01 00:00:00

abstract：OBJECTIVES:Autism spectrum disorders (ASDs) have core impairments in social communication as well as the presence of repetitive, stereotypic behaviors and restricted interests. Older adolescents and young adults are particularly impacted by these deficits. Preclinical data implicate glutamatergic dysfunction in the pat...

journal_title：Clinical neuropharmacology

authors： Urbano M,Okwara L,Manser P,Hartmann K,Herndon A,Deutsch SI

更新日期：2014-05-01 00:00:00

abstract：OBJECTIVE:The purpose of this study is to investigate the safety and efficacy of aripiprazole in first-episode drug-naive patients with schizophrenia. METHODS:A total of 45 patients were enrolled in an open-label 12-week study. Dosing was determined by clinical judgment. The main efficacy measure was the Brief Psychia...

journal_title：Clinical neuropharmacology

authors： Takahashi H,Oshimo T,Ishigooka J

更新日期：2009-05-01 00:00:00

abstract：:Two patients with essential tremor who had no psychiatric history developed symptoms of psychosis (visual hallucinations, paranoia, and vivid dreams) 3 days after starting topiramate (25 mg BID) for tremor control. All adverse symptoms resolved several days after topiramate was discontinued. ...

journal_title：Clinical neuropharmacology

authors： Zesiewicz TA,Tullidge A,Tidwell J,Sullivan KL,Hauser RA

更新日期：2006-05-01 00:00:00

abstract：:The effect of bromocriptine at doses up to 20 mg/day was studied in a single-blind format with a placebo phase in 15 Parkinson's disease patients with mild-to-moderate disability who had not been previously treated with levodopa. For the 11 patients who completed the 9 month trial, both Northwestern University Disabil...

journal_title：Clinical neuropharmacology

authors： Tolosa E,Blesa R,Bayes A,Forcadell F

更新日期：1987-04-01 00:00:00

abstract：:Fluctuations in motor performance are the major problems in chronic management of Parkinson's disease. Most of these fluctuations reflect the decline of levodopa availability. As a consequence, levodopa dosage might be increased and the interdose interval progressively shortened. The postsynaptic dopamine receptors at...

journal_title：Clinical neuropharmacology

authors： Stocchi F,Patsalos PN,Berardelli A,Barbato L,Bonamartini A,Manfredi M,Ruggieri S

更新日期：1994-01-01 00:00:00

abstract：:In rodents, serotonin (5-HT) antagonists counteract behavioral and biochemical effects of neuroleptic drugs. Therefore, we have studied the effect of different 5-HT drugs and one anticholinergic drug in acute dystonia in five cebus monkeys chronically treated with haloperidol. Acute dystonia induced by subcutaneous in...

journal_title：Clinical neuropharmacology

authors： Povlsen UJ,Noring U,Laursen AL,Korsgaard S,Gerlach J

更新日期：1986-01-01 00:00:00

abstract：:Newly introduced dopamine agonists, such as ropinirole, may offer advantages compared to such older drugs as bromocriptine in patients with advanced Parkinson's disease (PD) with response oscillations or waning efficacy. Dose equivalence of these two drugs, however, has not been well established, which may complicate ...

journal_title：Clinical neuropharmacology

authors： Giménez-Roldán S,Esteban EM,Mateo D

更新日期：2001-11-01 00:00:00

abstract：:Glutamine synthetase (GS), an enzyme localized in astroglial cells in the brain, is directly implicated in brain detoxification. An ontogenic study of GS activity was performed in homogenates from four distinct brain areas in comparison with the respective astrocytes obtained in primary cultures. GS was induced by hyd...

journal_title：Clinical neuropharmacology

authors： Tardy M,Rolland B,Fages C,Caldani M

更新日期：1984-01-01 00:00:00